Eli Lilly logo

Eli Lilly’s COVID-19 Antibody Cocktail Receives EMA Review

February 9, 2021

The European Medicines Agency (EMA) is reviewing Eli Lilly’s antibody cocktail as a potential treatment for COVID-19 patients who don’t require supplemental oxygen and are at high risk of progressing to severe disease.

Preliminary study data on Lilly’s bamlanivimab/etesevimab cocktail showed the combination treatment reduced viral load as well as COVID-19-associated medical visits and hospitalizations and the EMA’s human medicines committee is considering a recommendation for conditional marketing authorization.

Results from a phase 3 study showed the antibody cocktail reduced the risk of COVID-19 hospitalization or death by 70 percent.

View today's stories